Business Description
Medtide Inc
ISIN : CNE100006S86
Share Class Description:
FRA:FQ2: Ordinary Shares - Class HTotal Employee Number:
566Compare
Compare
Traded in other countries / regions
03880.Hong KongFQ2.Germany IPO Date
2025-07-16Description
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 33.26 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.15 | |||||
Interest Coverage | 196.63 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 8.85 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.5 | |||||
3-Year EBITDA Growth Rate | 46.1 | |||||
3-Year EPS without NRI Growth Rate | 68.2 | |||||
3-Year FCF Growth Rate | 50.3 | |||||
3-Year Book Growth Rate | 97.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.09 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.67 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.43 | |||||
9-Day RSI | 37.92 | |||||
14-Day RSI | 41.28 | |||||
3-1 Month Momentum % | 10.19 | |||||
6-1 Month Momentum % | -9.85 | |||||
12-1 Month Momentum % | -38.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.17 | |||||
Quick Ratio | 5.55 | |||||
Cash Ratio | 5.13 | |||||
Days Inventory | 185.03 | |||||
Days Sales Outstanding | 25.75 | |||||
Days Payable | 42.23 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.12 | |||||
Operating Margin % | 37.63 | |||||
Net Margin % | 30.54 | |||||
EBITDA Margin % | 38.59 | |||||
FCF Margin % | 24.3 | |||||
OCF Margin % | 47.28 | |||||
ROE % | 10.83 | |||||
ROA % | 9.33 | |||||
ROIC % | 24.93 | |||||
3-Year ROIIC % | -37.6 | |||||
ROC (Joel Greenblatt) % | 47.38 | |||||
ROCE % | 12.48 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.67 | |||||
Forward PE Ratio | 10.47 | |||||
PE Ratio without NRI | 15.52 | |||||
Price-to-Owner-Earnings | 11.89 | |||||
PS Ratio | 4.79 | |||||
PB Ratio | 1.57 | |||||
Price-to-Tangible-Book | 1.69 | |||||
Price-to-Free-Cash-Flow | 19.73 | |||||
Price-to-Operating-Cash-Flow | 10.12 | |||||
EV-to-EBIT | 8.12 | |||||
EV-to-EBITDA | 7.57 | |||||
EV-to-Revenue | 2.92 | |||||
EV-to-FCF | 12.64 | |||||
Price-to-Graham-Number | 1.08 | |||||
| Price-to-Net-Current-Asset-Value | 2.6 | |||||
| Price-to-Net-Cash | 3.25 | |||||
Earnings Yield (Greenblatt) % | 12.32 | |||||
FCF Yield % | 5.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medtide Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 68.396 | ||
| EPS (TTM) (€) | 0.147 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 20.52 | ||
| 14-Day RSI | 41.28 | ||
| 14-Day ATR (€) | 0.084908 | ||
| 20-Day SMA (€) | 2.28 | ||
| 12-1 Month Momentum % | -38.66 | ||
| 52-Week Range (€) | 2.08 - 3.92 | ||
| Shares Outstanding (Mil) | 141.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medtide Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medtide Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medtide Inc Frequently Asked Questions
What is Medtide Inc(FRA:FQ2)'s stock price today?
The current price of FRA:FQ2 is €2.18. The 52 week high of FRA:FQ2 is €3.92 and 52 week low is €2.08.
When is next earnings date of Medtide Inc(FRA:FQ2)?
The next earnings date of Medtide Inc(FRA:FQ2) is .
Does Medtide Inc(FRA:FQ2) pay dividends? If so, how much?
Medtide Inc(FRA:FQ2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Medtide Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers